CAR T-cell Therapy Market Growth Forecast

The global CAR T cell market is projected to grow from USD 6.78 billion in 2026 to USD 13.56 billion by 2031, with a CAGR of 14.9%. This growth is fueled by the rising prevalence of cancer, increased investments in immunotherapies, and continuous technological advancements in CAR T-cell treatment. CAR T cell, a personalized cancer treatment, is gaining adoption due to its targeted responses in hematologic malignancies, clinical success, and expanding regulatory approvals. Ciltacabtagene autoleucel held the largest market share in 2025, attributed to its efficacy in treating multiple myeloma. B-cell lymphoma is the leading indication segment, and CD19 is the dominant target type. North America, particularly the United States, leads the market due to advanced healthcare infrastructure, early adoption, and strong regulatory support from the United States===Food and Drug Administration. Key players include Bristol Myers Squibb, Gilead Sciences, Novartis, Johnson & Johnson, and JW (Cayman) Therapeutics, who are focusing on innovation and strategic collaborations.